Differential (Click to cross reference) aducanumab adverse drug reaction Alzheimer's disease Alzheimer's disease, early onset Alzheimer's disease, treatment of amyloid beta protein amyloid beta protein antibodies amyloid-related imaging abnormalities apolipoprotein E apoliprotein E, plasma level biologic markers CAT scan, emission, abnormal cerebral edema cerebral edema, vasogenic cerebrovascular disease complications confusion contraindications controversies in neurology cost dementia dementia, treatment of dizziness gantenerumab headache hemosiderosis of CNS, superficial hemosiderosis, subarachnoid iatrogenic neurologic disorders intracerebral hemorrhage intracerebral hemorrhage, small lecanemab mental status, abnormal microhemorrhage, intracerebral mild cognitive impairment monoclonal antibodies MRI, abnormal myoclonus prognosis remternetug risk factors safety shared decision making tissue plasminogen activator, intravenous treatment of neurologic disorder white matter disease

Showing articles 0 to 5 of 5 Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease JAMA Neurol 92:19-29, Salloway,S.,et al, 2025 Lecanemab in Early Alzheimers Disease NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023 Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment Neurol 101:1079-1080, Bonami,S.,et al, 2023 Amyloid-Related Imaging Abnormalities:An Update AJR 220:562-575, Roytman,M.,et al, 2023 Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021 Showing articles 0 to 5 of 5